NICE guidance on sotagliflozin for type 1 diabetes
Publication date: Available online 24 February 2020Source: The Lancet Diabetes &EndocrinologyAuthor(s): Amanda I Adler, Jessica Cronshaw, Carl Prescott, Sanjeev Patel, Eleanor Donegan, Jasdeep Hayre
If you or your child has type 1 diabetes, you already have a lot of extra health worries, and now you need to add COVID-19 infections to the list.
Publication date: Available online 9 April 2020Source: Canadian Journal of DiabetesAuthor(s): Judith B. Brown, Yashoda Valliere, Cecelia McLachlan, Sonja M. Reichert, Susan Webster-Bogaert, Alexandria Ratzki-Leewing, Bridget L. Ryan, Stewart B. Harris
AbstractAims/hypothesisWe aimed to assess whether persistence of C-peptide secretion is associated with less glucose variability and fewer low-glucose events in adults with type 1 diabetes who use flash monitoring.MethodsWe performed a cross-sectional study of 290 adults attending a university teaching hospital diabetes clinic, with type 1 diabetes, who use flash monitoring and in whom a random plasma C-peptide was available in the past 2 years. Variables relating to flash monitoring were compared between individuals with low C-peptide (
Conclusions/interpretationOur analysis identifies a range of demographic and environmental factors associated with type 1 diabetes in children in England.
AbstractFrustratingly, disease-modifying treatments for diabetic neuropathy remain elusive. Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but not in those with type 2 diabetes, which constitute the vast majority of patients. Encouragingly, recent evidence points to new metabolic risk factors and mechanisms, and thus also at novel disease-modifying strategies, which are desperately needed. Obesity has emerged as the second most important metabolic risk factor for neuropathy (diabetes being the first) from consensus findings of seven observational studies in populations across the ...
Conclusions/interpretationOur data suggest that systemic dysregulation of lipid metabolism, as observed in plasma, may impact the metabolism and function of immune cells during progression to overt type 1 diabetes.Data availabilityThe GEMs for PBMCs have been submitted to BioModels (www.ebi.ac.uk/biomodels/), under accession number MODEL1905270001. The metabolomics datasets and the clinical metadata generated in this study were submitted to MetaboLights (https://www.ebi.ac.uk/metabolights/), under accession number MTBLS1015.
Conclusions/interpretationThe present data support the possibility that HMGB1 could be a viable therapeutic target to prevent the initiation, progression and recurrence of autoimmunity in the setting of type 1 diabetes.
Authors: Li S, Hu Y, Tan X, Wang D, Hu J, Zou P, Wang L Abstract Introduction: Hypoglycemia in diabetes is a common and unresolved complication during diabetes therapy, even life-threatening. Effective and convenient treatment for rescuing severe diabetic hypoglycemia and maintaining euglycemia is in high demand to reduce hypoglycemia-related morbidity and mortality. Dasiglucagon is a novel glucagon analog for diabetic hypoglycemia therapy.Areas covered: This review summarizes the reported studies associated with the pharmacokinetics, pharmacodynamics, safety, and tolerability characteristics, as well as clinical a...
A generic vaccine that's shown promise in reversing type 1 diabetes long-term in trials at Massachusetts General Hospital will soon have a new target: the COVID-19 coronavirus.
THURSDAY, April 9, 2020 -- If you or your child has type 1 diabetes, you already have a lot of extra health worries, and now you need to add COVID-19 infections to the list. You may be wondering if you have a higher risk of catching COVID-19, if...